Persist AI Secures $12 Million in Series A Funding
Persist AI, a cutting-edge company based in Sacramento, CA, specializing in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), has successfully closed a Series A financing round, raising $12 million in total.
Key Points:
- The funding round was led by Spero Ventures, with contributions from various prominent investors including MBX Capital, Eli Lilly & Company, and SignalFire, among others.
- The company plans to utilize the funds to expand its robotic lab, enhance its AI models with comprehensive data sets, and broaden the scope of formulations that can be predicted, built, and tested by the AI models and robotic lab.
- Under the leadership of CEO Karthik Raman and COO Christopher Shelner, Persist AI combines predictive AI models with automated robotic systems to empower pharmaceutical companies in formulating drugs through a user-friendly website.
Persist AI’s innovative approach involves the use of predictive AI models and automated robotic systems to streamline the drug formulation process for pharmaceutical companies. By leveraging advanced technologies, the company aims to revolutionize the way drug formulations are developed and tested.
Advancing Pharmaceutical Research and Development
With the introduction of their Cloud Lab, pharmaceutical companies worldwide now have the opportunity to remotely access Persist AI’s cutting-edge robotic facilities for formulating and testing a wide range of pharmaceutical products. From long-acting injectables to topical formulations, the platform caters to various modalities, including peptides, antibodies, and small molecules.
Moreover, Persist AI’s collaboration with Nivagen Pharmaceuticals in Sacramento, CA, to establish a GMP manufacturing system for long-acting injectables signifies the company’s commitment to driving innovation in the pharmaceutical industry.
As a Y Combinator-backed startup, Persist AI has rapidly gained recognition for its groundbreaking approach to pharmaceutical formulation development. With a focus on enhancing efficiency and accuracy in drug development processes, Persist AI is poised to make a significant impact on the future of pharmaceutical research and development.
